Deutsche Bank set a €97.00 ($112.79) price target on Merck KGaA (FRA:MRK) in a research report sent to investors on Thursday, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
A number of other analysts have also weighed in on the stock. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Tuesday. Barclays set a €82.00 ($95.35) target price on shares of Merck KGaA and gave the stock a sell rating in a report on Friday, May 3rd. UBS Group set a €104.00 ($120.93) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Thursday, April 25th. Independent Research set a €103.00 ($119.77) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Tuesday, April 16th. Finally, DZ Bank reiterated a neutral rating on shares of Merck KGaA in a report on Tuesday, April 16th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of €100.95 ($117.38).
Shares of Merck KGaA stock traded down €0.12 ($0.14) during trading on Thursday, reaching €96.52 ($112.23). 447,869 shares of the stock were exchanged. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Read More: What is net income?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.